The Business of healthcare innovation / edited by Lawton Robert Burns
Material type:
TextPublication details: Cambridge, United Kingdom : Cambridge University Press, c2020Edition: Third EditionDescription: 492 pages : illustrations ; 25 cmISBN: - 9781108749060
- R 855.3 .B87 2020
Books
| Item type | Current library | Home library | Collection | Call number | Copy number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|---|---|
|
Books
|
National University - Manila | LRC - Main General Circulation | Pharmacy | GC R 855.3 .B87 2020 (Browse shelf(Opens below)) | c.1 | Available | NULIB000018939 |
Browsing LRC - Main shelves, Shelving location: General Circulation, Collection: Pharmacy Close shelf browser (Hides shelf browser)
|
|
|
|
|
|
|
||
| GC QR 67 .F67 2007 Bailey and Scott's Diagnostic Microbiology / | GC R 727.3 .T36 2008 Therapeutic communications for health professionals / | GC R 855.3 .A24 2015 Health technology assessment and health policy today : a multifaceted view of their unstable crossroads / | GC R 855.3 .B87 2020 The Business of healthcare innovation / | GC RA 410.53 .B73 2010 Health economics / | GC RA 410.56 .B47 2011 Essentials of health care marketing / | GC RA 410.56 .J67 2021 Pharmaceutical management and marketing / |
Includes bibliographical references and index.
1. Product suppliers in the health care value chain Lawton Robert Burns -- 2. The pharmaceutical sector Richard T. Evans and Scott Hinds -- 3. The biotechnology sector - therapeutics Cary G. Pfeffer -- 4. New venture creation in biotechnology Jason Rhodes and Lawton Robert Burns -- 5. The medical device sector Kurt H. Kruger and Max A. Kruger -- 6. Financing medtech innovation Justin Klein -- 7. The healthcare information technology sector Adam C. Powell and John Glaser.
Perhaps as never before, countries around the world are looking at biomedical innovation as a source of (a) knowledge creation by their scientific communities, (b) value creation for their populations, and (c) wealth creation by fostering industries and expansion of employment. In the U.S., for example, bipartisan passage of the 21st Century Cures Act of 2016 seeks to accelerate new product development and faster patient access to new treatments and therapies. It also elevates the role of biomedical research through an additional .3 billion in funding for the National Institutes of Health (NIH) and other agencies
There are no comments on this title.